Christine Messmer PC Takes Position in Merck & Co., Inc. $MRK

Christine Messmer PC bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 17,072 shares of the company’s stock, valued at approximately $1,797,000. Merck & Co., Inc. comprises approximately 1.2% of Christine Messmer PC’s holdings, making the stock its 20th largest position.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. D.A. Davidson & CO. boosted its stake in shares of Merck & Co., Inc. by 4.4% during the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after acquiring an additional 24,576 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Merck & Co., Inc. by 48.9% in the 4th quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock valued at $10,296,000 after buying an additional 32,114 shares in the last quarter. Coldstream Capital Management Inc. lifted its stake in Merck & Co., Inc. by 12.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock valued at $10,364,000 after buying an additional 13,940 shares in the last quarter. Campbell Capital Management Inc. purchased a new position in Merck & Co., Inc. in the 3rd quarter valued at about $1,866,000. Finally, NEOS Investment Management LLC lifted its stake in Merck & Co., Inc. by 39.9% in the 3rd quarter. NEOS Investment Management LLC now owns 347,684 shares of the company’s stock valued at $29,181,000 after buying an additional 99,074 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a research note on Friday, February 13th. Barclays initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price on the stock. Citigroup raised their target price on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, March 20th. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, TD Cowen raised their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Trading Up 0.8%

MRK opened at $113.05 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The company’s 50 day simple moving average is $117.69 and its two-hundred day simple moving average is $107.70. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14. The firm has a market capitalization of $279.21 billion, a price-to-earnings ratio of 31.84, a price-to-earnings-growth ratio of 2.27 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 26.84%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts expect that Merck & Co., Inc. will post 4.9 EPS for the current fiscal year.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — revenue of $16.29B, EPS ahead of consensus, and management maintained/raised FY?2026 guidance and reiterated growth drivers from oncology and new launches. MRK Q1 Deep Dive
• Positive Sentiment: Pipeline and M&A boost long?term thesis — recent FDA approval of the HIV regimen IDVYNSO, KEYTRUDA priority reviews and the Terns acquisition (adds TERN?701) support upside beyond Keytruda. Analysts and bulls point to these as offsetting Patent risks. Pipeline & Terns Acquisition
• Positive Sentiment: Analyst and media support — major firms (Wells Fargo, BMO) reaffirm buy ratings and commentators such as Jim Cramer highlighted the quarter as a turning point, which helps sentiment. Wells Fargo Buy Rating BMO Buy Rating Jim Cramer on MRK
• Neutral Sentiment: Institutional commentary — Baron Capital highlighted MRK in its Q1 letter as an investment case, reflecting continued institutional interest but not immediate catalyst. Baron Capital Letter
• Negative Sentiment: Technical/price risk — chart analysts flag a confirmed double?top breakdown and moving?average resistance that could open a deeper correction, increasing short?term downside risk despite fundamentals. Double Top Technical Risk
• Negative Sentiment: Sector rotation and shorter?term profit?taking — some sell pressure in pharma after strong earnings days for the sector has weighed on MRK intermittently, tempering the rally. Sector Sentiment Note

Insider Activity

In other news, EVP Richard R. Deluca sold 37,685 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the sale, the executive vice president owned 160,174 shares of the company’s stock, valued at approximately $19,368,240.08. The trade was a 19.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the sale, the chief marketing officer directly owned 70,615 shares in the company, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 320,176 shares of company stock worth $38,281,735. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.